Xvivo Perfusion Ab Stock Fundamentals
| XVIPYDelisted Stock | USD 5.70 0.53 8.51% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Xvivo Perfusion's long-term financial health and intrinsic value.
Xvivo |
Xvivo Perfusion AB Company Debt To Equity Analysis
Xvivo Perfusion's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Xvivo Perfusion Debt To Equity | 0 % |
Most of Xvivo Perfusion's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Xvivo Perfusion AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, Xvivo Perfusion AB has a Debt To Equity of 0.004%. This is much higher than that of the sector and significantly higher than that of the Debt To Equity industry. The debt to equity for all United States stocks is notably lower than that of the firm.
Xvivo Perfusion AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Xvivo Perfusion's current stock value. Our valuation model uses many indicators to compare Xvivo Perfusion value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Xvivo Perfusion competition to find correlations between indicators driving Xvivo Perfusion's intrinsic value. More Info.Xvivo Perfusion AB is rated second in return on equity category among its peers. It is rated third in return on asset category among its peers reporting about 0.24 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Xvivo Perfusion AB is roughly 4.10 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Xvivo Perfusion by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Xvivo Perfusion's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Xvivo Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Xvivo Perfusion's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Xvivo Perfusion could also be used in its relative valuation, which is a method of valuing Xvivo Perfusion by comparing valuation metrics of similar companies.Xvivo Perfusion is currently under evaluation in debt to equity category among its peers.
Xvivo Fundamentals
| Return On Equity | 0.025 | |||
| Return On Asset | 0.0061 | |||
| Profit Margin | 0.08 % | |||
| Gross Profit | 188.28 M | |||
| Net Income | 8.15 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 6.48 X | |||
| Cash Flow From Operations | (12.06 M) | |||
| Number Of Employees | 118 | |||
| Beta | 1.92 |
About Xvivo Perfusion Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xvivo Perfusion AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xvivo Perfusion using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xvivo Perfusion AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Xvivo Perfusion AB , a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden. Xvivo Perfusion is traded on OTC Exchange in the United States.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Xvivo Pink Sheet
If you are still planning to invest in Xvivo Perfusion AB check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Xvivo Perfusion's history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |